Polar Asset Management Partners Inc. Purchases 509,992 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Polar Asset Management Partners Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 1,240.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 551,092 shares of the company's stock after buying an additional 509,992 shares during the quarter. Polar Asset Management Partners Inc. owned 0.38% of Denali Therapeutics worth $11,231,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after buying an additional 843,996 shares during the last quarter. FMR LLC grew its holdings in Denali Therapeutics by 2.4% in the 4th quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after buying an additional 188,368 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Denali Therapeutics by 8.8% in the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after buying an additional 268,378 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Denali Therapeutics by 6.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock valued at $62,335,000 after buying an additional 188,820 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock valued at $37,805,000 after buying an additional 295,594 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded up $0.36 during trading hours on Tuesday, hitting $14.27. 175,526 shares of the stock were exchanged, compared to its average volume of 1,092,379. The stock has a market capitalization of $2.07 billion, a P/E ratio of -5.15 and a beta of 1.49. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The business's 50-day moving average is $14.07 and its two-hundred day moving average is $19.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period in the previous year, the company earned ($0.68) EPS. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on DNLI. Oppenheimer cut their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Robert W. Baird cut their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research report on Thursday, May 8th. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective for the company. Finally, William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.